PA8583501A1 - Derivados de pirrolidona como inhibidores de maob - Google Patents

Derivados de pirrolidona como inhibidores de maob

Info

Publication number
PA8583501A1
PA8583501A1 PA20038583501A PA8583501A PA8583501A1 PA 8583501 A1 PA8583501 A1 PA 8583501A1 PA 20038583501 A PA20038583501 A PA 20038583501A PA 8583501 A PA8583501 A PA 8583501A PA 8583501 A1 PA8583501 A1 PA 8583501A1
Authority
PA
Panama
Prior art keywords
derivatives
pirrolidone
maob inhibitors
maob
inhibitors
Prior art date
Application number
PA20038583501A
Other languages
English (en)
Inventor
Rene Wyler
Andrew William Thomas
Rosa Maria Rodriguez Sarmiento
Synese Jolidon
Hans Iding
Beat Wirz
Daniela Krummenacher
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8583501A1 publication Critical patent/PA8583501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE 4-PIRROLIDINO RACEMICOS O ENANTIOMERICAMENTE PUROS, PROCESOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS DERIVADOS, Y SU USO EN LA PREVENCION Y TRATAMIENTO DE UNA ENFERMEDADAD QUE ESTA MEDIADA POR EL INHIBIDOR DE LA MONOAMINA OXIDASA B, EN PARTICULAR LA ENFERMEDAD DE ALZHEIMER Y DEMENCIA SENIL.
PA20038583501A 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob PA8583501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20

Publications (1)

Publication Number Publication Date
PA8583501A1 true PA8583501A1 (es) 2004-04-23

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
PA20038583001A PA8583001A1 (es) 2002-09-20 2003-09-17 Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
PA20038583601A PA8583601A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob
PA20038583501A PA8583501A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PA20038583001A PA8583001A1 (es) 2002-09-20 2003-09-17 Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
PA20038583601A PA8583601A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob

Country Status (32)

Country Link
US (4) US7151111B2 (es)
EP (3) EP1542969B1 (es)
JP (3) JP4335141B2 (es)
KR (3) KR100676015B1 (es)
CN (3) CN100503562C (es)
AR (3) AR041299A1 (es)
AT (2) ATE472530T1 (es)
AU (3) AU2003267381B2 (es)
BR (4) BRPI0314631B1 (es)
CA (3) CA2498335A1 (es)
CY (1) CY1110745T1 (es)
DE (2) DE60331559D1 (es)
DK (1) DK1542970T3 (es)
ES (2) ES2338646T3 (es)
GT (3) GT200300204A (es)
HK (3) HK1084383A1 (es)
HR (3) HRP20050261A2 (es)
JO (2) JO2604B1 (es)
MX (3) MXPA05002881A (es)
MY (3) MY134480A (es)
NO (3) NO329754B1 (es)
NZ (3) NZ538048A (es)
PA (3) PA8583001A1 (es)
PE (3) PE20050077A1 (es)
PL (3) PL376018A1 (es)
PT (1) PT1542970E (es)
RU (3) RU2323209C2 (es)
SI (1) SI1542970T1 (es)
TW (3) TWI286132B (es)
UY (3) UY27990A1 (es)
WO (3) WO2004026826A1 (es)
ZA (3) ZA200501137B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8583001A1 (es) * 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
US7456210B2 (en) * 2004-08-02 2008-11-25 Hoffmann-La Roche Inc. Benzyloxy derivatives
EP1855655A2 (en) 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Tablets with improved drug substance dispersibility
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
CN101142181B (zh) * 2005-03-15 2011-05-04 弗·哈夫曼-拉罗切有限公司 对映异构纯的4-吡咯烷子基苯基苄基醚衍生物的制备方法
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
CA2706017A1 (en) * 2007-03-30 2008-10-09 Jorge R. Barrio In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
AU2014241759B2 (en) 2013-03-14 2017-10-19 Dart Neuroscience (Cayman) Ltd. Substituted naphthyridine and quinoline compounds as MAO inhibitors
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
BR112016003288A8 (pt) 2013-10-29 2020-02-04 Hoffmann La Roche processos para sintetizar n-[(3s)-1-[4-[(3-fluorofenil)metóxi]fenil]-5-oxo-pirrolidin-3-il]acetamida cristalina, e seu intermediário
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
EP3273946A1 (en) 2015-03-27 2018-01-31 F. Hoffmann-La Roche AG Pharmaceutical formulation comprising sembragiline
US11365194B2 (en) 2017-09-27 2022-06-21 Kagoshima University Analgesic drug using PAC1 receptor antagonistic drug
SG10202112966SA (en) 2017-10-05 2021-12-30 Biogen Inc Process for preparing αlpha-carboxamide pyrrolidine derivatives
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
CN110240557B (zh) * 2018-03-08 2023-05-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物及其用途
EP3932490A4 (en) 2019-02-27 2022-11-16 Kagoshima University ANTIPRURIC AGENT USING PAC1 RECEPTOR ANTAGONISTS
US20230181587A1 (en) 2020-05-08 2023-06-15 Kagoshima University Antidepressant/anxiolytic drug in which pac1 receptor antagonist is used
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
DK0393607T3 (da) 1989-04-19 1996-03-18 Otsuka Pharma Co Ltd Phenylcarboxylsyrederivater med en heteroring
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
AU709323B2 (en) 1996-03-15 1999-08-26 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
EP1165546A2 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
US7621863B2 (en) * 2000-02-10 2009-11-24 Obtech Medical Ag Urinary incontinence treatment with wireless energy supply
AU2001232586A1 (en) * 2000-02-14 2001-07-09 Potencia Medical Ag Penile prosthesis
PA8583001A1 (es) * 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism

Also Published As

Publication number Publication date
AU2003273901B2 (en) 2008-07-10
UY27991A1 (es) 2004-03-31
NO20050701L (no) 2005-03-02
PE20050077A1 (es) 2005-03-01
ZA200501311B (en) 2006-10-25
CA2498335A1 (en) 2004-04-01
GT200300205A (es) 2004-04-29
PL376019A1 (en) 2005-12-12
UY27993A1 (es) 2004-03-31
US20040106650A1 (en) 2004-06-03
PE20050078A1 (es) 2005-02-28
BR0314314A (pt) 2005-07-26
NO329754B1 (no) 2010-12-13
CA2498785A1 (en) 2004-04-01
WO2004026826A1 (en) 2004-04-01
RU2323209C2 (ru) 2008-04-27
TWI337604B (en) 2011-02-21
ATE472530T1 (de) 2010-07-15
US7037935B2 (en) 2006-05-02
MY134480A (en) 2007-12-31
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
NZ538046A (en) 2007-08-31
CA2496756A1 (en) 2004-04-01
TW200413350A (en) 2004-08-01
GT200300206A (es) 2004-04-29
AU2003270213A1 (en) 2004-04-08
JP2006503834A (ja) 2006-02-02
RU2336267C2 (ru) 2008-10-20
RU2005111969A (ru) 2006-01-20
ATE459601T1 (de) 2010-03-15
NO20050652L (no) 2005-03-08
KR100681586B1 (ko) 2007-02-09
MY135696A (en) 2008-06-30
EP1542969A1 (en) 2005-06-22
MY133332A (en) 2007-11-30
US7235581B2 (en) 2007-06-26
PE20050079A1 (es) 2005-03-01
NZ538049A (en) 2007-05-31
HRP20050263B1 (hr) 2013-09-30
PA8583601A1 (es) 2004-09-16
US7122562B2 (en) 2006-10-17
MXPA05002880A (es) 2005-05-27
AR041297A1 (es) 2005-05-11
BR0314299A (pt) 2005-12-13
AU2003267381B2 (en) 2009-08-27
JO2604B1 (en) 2011-11-01
CN1681778A (zh) 2005-10-12
CN100383118C (zh) 2008-04-23
KR100676014B1 (ko) 2007-01-30
CA2496756C (en) 2012-01-10
PL376018A1 (en) 2005-12-12
BR0314631A (pt) 2005-08-02
CN100503562C (zh) 2009-06-24
KR20050057450A (ko) 2005-06-16
JP4335140B2 (ja) 2009-09-30
CN100400509C (zh) 2008-07-09
PA8583001A1 (es) 2004-04-23
US20040097578A1 (en) 2004-05-20
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
NO330012B1 (no) 2011-02-07
DE60331559D1 (de) 2010-04-15
JP4335141B2 (ja) 2009-09-30
TW200410935A (en) 2004-07-01
CN1681779A (zh) 2005-10-12
PL376021A1 (en) 2005-12-12
AU2003273901A1 (en) 2004-04-08
AU2003270213B2 (en) 2009-02-12
TW200408624A (en) 2004-06-01
MXPA05002878A (es) 2005-05-27
HRP20050263A2 (en) 2006-12-31
AU2003267381A1 (en) 2004-04-08
JP2006510596A (ja) 2006-03-30
NZ538048A (en) 2007-05-31
NO20050665L (no) 2005-04-18
ES2344557T3 (es) 2010-08-31
TWI286132B (en) 2007-09-01
ES2338646T3 (es) 2010-05-11
HK1083498A1 (en) 2006-07-07
SI1542970T1 (sl) 2010-08-31
TWI331994B (en) 2010-10-21
ZA200501137B (en) 2006-12-27
EP1542971A1 (en) 2005-06-22
AR041298A1 (es) 2005-05-11
DE60333202D1 (de) 2010-08-12
HRP20050261A2 (en) 2006-05-31
RU2005111968A (ru) 2006-11-10
US20060122235A1 (en) 2006-06-08
US7151111B2 (en) 2006-12-19
RU2336268C2 (ru) 2008-10-20
KR20050057456A (ko) 2005-06-16
CN1681777A (zh) 2005-10-12
HK1083499A1 (en) 2006-07-07
DK1542970T3 (da) 2010-08-02
ZA200501557B (en) 2005-09-08
AR041299A1 (es) 2005-05-11
JP2006503833A (ja) 2006-02-02
US20040116707A1 (en) 2004-06-17
GT200300204A (es) 2004-04-29
PT1542970E (pt) 2010-07-19
BRPI0314631B1 (pt) 2018-04-17
EP1542970B1 (en) 2010-06-30
WO2004026825A1 (en) 2004-04-01
CA2498785C (en) 2011-07-26
HK1084383A1 (en) 2006-07-28
KR100676015B1 (ko) 2007-01-30
KR20050057466A (ko) 2005-06-16
RU2005111974A (ru) 2006-01-20
CY1110745T1 (el) 2015-06-10
JP4335142B2 (ja) 2009-09-30
WO2004026827A1 (en) 2004-04-01
UY27990A1 (es) 2004-03-31
HRP20050262A2 (en) 2006-06-30
AU2003270213B8 (en) 2009-03-05
JO2605B1 (en) 2011-11-01

Similar Documents

Publication Publication Date Title
PA8583501A1 (es) Derivados de pirrolidona como inhibidores de maob
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
ECSP045429A (es) Combinacion de compuestos organicos
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
AR050717A1 (es) Composiciones farmaceuticas
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
RS52945B (en) PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
ECSP088786A (es) Tratamientos de las alergias oculares
NO20083836L (no) N-hydroksyakrylamidforbindelser
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
UY27018A1 (es) Derivados de la pirimidina
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
RS54185B1 (en) USE OF 24-ORDER
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
EA200500326A1 (ru) Применение ферментированного экстракта проростков пшеницы в качестве противовоспалительного агента